Piotr J. Wysocki

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Sun Young Rha, Do‐Youn Oh, Patricio Yañez et al. · The Lancet Oncology · 2023 · 521 citations

Chemotherapy Versus Placebo, Gastrointestinal Oncology, Medicine +8

Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial

Thomas Powles, Kobe Yuen, Silke Gillessen et al. · Nature Medicine · 2022 · 231 citations · Full text

Urology, Medicine, Enzalutamide Versus +7

BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd).

Peter Schmid, Seock‐Ah Im, Anne Armstrong et al. · Journal of Clinical Oncology · 2021 · 105 citations

Poor Clinical Outcomes, Breast Oncology, Immunology +23

Abstract CT014: IMbassador250: A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC)

Christopher J. Sweeney, Silke Gillessen, Dana E. Rathkopf et al. · Cancer Research · 2020 · 62 citations

Current Treatments, Immunology, Enza 160 +20

Complete tumour regressions induced by vaccination with IL-12 gene-transduced tumour cells in combination with IL-15 in a melanoma model in mice

Nadzieja Drela, Ahmad Jalili, Rafał Kamiński et al. · Cancer Immunology Immunotherapy · 2004 · 50 citations · Full text

Immune Evasion, Complete Tumour Regressions, Immunology +10